Clinical trial Recruiting at 1 site Observational Ages 18 and up

ABL90 FLEX PLUS HEM device performance for hemolysis detection

Official title: Feasibility Performance Study Protocol for ABL90 FLEX PLUS HEM

Run by Radiometer Medical ApS · NCT07345091 · Data updated 2026-11-12

This will test whether the ABL90 FLEX PLUS HEM device can accurately detect hemolysis in arterial or venous whole blood samples from adults.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment95 (estimated)
SponsorRadiometer Medical ApS
Industry-sponsored
Locations1 site (Copenhagen, NV)
StatusRecruiting
StartedAugust 4, 2025
Main results expectedMay 10, 2026
Study endsJune 10, 2026
Registry record updatedJanuary 15, 2026
Trial IDNCT07345091 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18 or older who can give informed consent (or have a legally designated representative if temporarily incapacitated) and who provide arterial or venous whole blood samples at the participating site.

Probably not a fit

Pregnant or breastfeeding individuals, those who cannot provide valid consent, or patients for whom sample collection would pose unnecessary risk are excluded and will not receive potential benefit from participation.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The study will test whole blood samples on the ABL90 FLEX PLUS HEM device and compare its hemolysis-detection results to an established reference method. Testing will be done at a single clinical site by trained personnel following a predefined protocol to ensure consistency. The primary focus is the analytical performance and feasibility of the hemolysis detection function in a real clinical environment. Results will be used to inform future clinical work and potential regulatory submissions.

Why it matters

Potential benefit: If successful, the device could provide faster, reliable point-of-care detection of hemolysis and help reduce repeat blood draws and result delays.

How similar studies have gone: Related hemolysis-detection features on blood gas analyzers have shown promising laboratory validation, but published clinical feasibility data are limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Subject must be 18 years of age or older
* Informed consent is obtained:

  * Directly from the subject, if they are competent and able to understand the provided information and voluntarily agree to participate, or
  * If the subject is temporarily incapacitated and unable to provide informed consent at the time of sample collection, written informed consent will be obtained from the subject's legally designated representative (LDR). when the subject regains capacity after enrollment, they will be informed of study inclusion and given the opportunity to withdraw consent.
* Subject evaluated as suitable according to the protocol and for the study by the principal investigator or designee.

Exclusion Criteria:

* Subject where sample collection is evaluated by PI or designee to impose unnecessary risk.
* Subject with an invalid written informed consent or who has withdrawn consent.
* Subject with known pregnancy or who is breastfeeding.

Where it's running

  • Bispebjerg Hospital
    Copenhagen, Nv, Denmark
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.